Marta Zalacain

Pamplona, NC, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Toxicity and Biodistribution of the Oncolytic Virus VCN-01 Following Intracranial Injection in Syrian Hamsters.

Toxicity and Biodistribution of the Oncolytic Virus VCN-01 Following Intracranial Injection in Syrian Hamsters.

Journal: Human gene therapy
Published: August 29, 2025

Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas.

Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas.

Journal: Cell reports. Medicine
Published: October 08, 2024

The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models.

The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models.

Journal: Neuro-oncology
Published: March 30, 2024

TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory.

TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory.

Journal: Cancer cell
Published: February 07, 2023

Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma.

Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma.

Journal: The New England journal of medicine
Published: June 29, 2022

Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma.

Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma.

Journal: Molecular therapy oncolytics
Published: April 04, 2022

Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas.

Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas.

Journal: JCI insight
Published: September 14, 2021

Clinical Value of NGS Genomic Studies for Clinical Management of Pediatric and Young Adult Bone Sarcomas.

Clinical Value of NGS Genomic Studies for Clinical Management of Pediatric and Young Adult Bone Sarcomas.

Journal: Cancers
Published: September 08, 2021

Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory.

Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory.

Journal: Molecular cancer therapeutics
Published: June 29, 2021

CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models.

CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models.

Journal: Journal for immunotherapy of cancer
Published: June 16, 2021

Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET.

Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 26, 2020

Local administration of IL-12 with an HC vector results in local and metastatic tumor control in pediatric osteosarcoma.

Local administration of IL-12 with an HC vector results in local and metastatic tumor control in pediatric osteosarcoma.

Journal: Molecular therapy oncolytics
Published: July 12, 2020
Showing 1-12 of 21

Last Updated: 09/26/2026